India is carving a path to reach its ambitious target UD$ 2 trillion economy, as the DGFT has said that India will have to undertake a slew of measures to reach its target by 2030. ...

Post-COVID-19, India needs to strengthen its pharma R&D ecosystem to tap into emerging drug development opportunities and changing paradigms in the new drug development framework.....

Dr. DK Srivastava, Chief Policy Advisor, EY India, proposes a three-phase roadmap for the public sector and private sector to strengthen India's manufacturing prowess in line with evolving technologie...

Sanjay Singh, Partner – Deal Advisory, Head of Lifesciences, KPMG in India, identifies new generics opportunities, established manufacturing ecosystem, growing penetration of health insurance and ta...

Though a new guideline released by the General Office of the State Council, China has revised the registration and approval of pharmaceutical products to fasten the process, the implementation still n...